Table 3. Generalized estimating equation analysis results used to determine the longitudinal trends of the resistin levels of the 513 patients with chronic hepatitis C who had completed the anti-hepatitis C virus (HCV) therapy.

Variants	Estimated Exp (B)	95% CI of estimated Exp (B)	P values
Gender (female)	1.844	0.178 ~ 19.892	0.608
Age (yr)	1.001	0.912 ~ 1.098	0.989
BMI	0.874	0.606 ~ 1.26	0.47
IFNL3 or IL28B rs12979860 CC genotype (1/0)	0.971	0.293 ~ 3.217	0.961
HCV genotype	0.643	0.143 ~ 2.898	0.565
HCV RNA (log10IU/mL)	1.009	0.933 ~ 1.091	0.823
RETN score #	13.904	5.699 ~ 33.921	< 0.001*
Therapy intervention (without)	0.018	0.001 ~ 0.288	0.005*
Therapy duration	0.821	0.599 ~ 1.125	0.22
SVR (0)	0.029	0.003 ~ 0.294	0.003*
HOMA-IR	0.972	0.856 ~ 1.103	0.659
TC (mg/dL)	0.959	0.92 ~ 1.00	0.051
TGs (mg/dL)	1.008	0.995 ~ 1.02	0.235
ALT (U/L)	0.988	0.978 ~ 0.998	0.017*
hsCRP (mg/L )	1.068	0.883 ~ 1.291	0.501
APRI	1.000	1.000 ~ 1.001	0.03*
Ferritin (ng/ml)	1.001	1.000 ~ 1.003	0.076
WBC count (103/uL)	2.263	1.075 ~ 4.765	0.032*
Platelet (103/uL)	0.954	0.89 ~ 1.024	0.191
C3 (mg/dL)	1.033	0.977 ~ 1.091	0.257
C4 (mg/dL)	0.937	0.85 ~ 1.032	0.186
GFR (ml /min/1.73 m2)	0.984	0.942 ~ 1.027	0.459
TSH (uU/mL)	1.001	0.993 ~ 1.009	0.778

95% CI of estimated Exp(B). BMI: body mass index; IFNL3 or IL28B: interferon-λ3 or interleukin 28B; log: logarithmic; RETN: resistin; HOMA-IR: homeostasis model assessment-estimated insulin resistance: TC: total cholesterol; TGs: triglycerides; ALT: alanine aminotransferase; hsCRP: high sensitivity C- reactive protein; APRI: AST to platelet ratio index; WBC: white blood cells; C3: complement component 3; C4: complement component 4; GFR: glomerular filtration rate; TSH: thyroid- stimulating hormone. #numbers of hyper-resistinemic genotypes of the 4 RETN SNPs including rs1423096, rs34861192, rs3745367 and rs3219175. *p < 0.05.